SBIR Banner

You are here

Investor Initiatives for NCI SBIR Awardees

Let NCI SBIR Connect Your Company with Potential Investors




The National Cancer Institute Small Business Innovation Research Development Center (NCI SBIR) is interested in connecting SBIR- and STTR-funded companies with potential investors and strategic partners to continue the research and commercialization efforts initially funded by NCI. To help facilitate the connection, NCI SBIR has been organizing Investor Initiatives as a means to connect companies with targeted investors and strategic partners on a regular basis throughout the year. The NCI SBIR Investor Initiatives program provides selected SBIR companies with resources to present at national showcases where they can explore partnering and investment opportunities.

2022 Program

Participation in the Investor Initiatives will be determined on a competitive basis as determined using an annual application process. This application is intended to be used for all of NCI’s Investor Initiatives starting in late summer 2022 through spring 2023. NCI also uses the outcomes of this program to recommend companies to the NIH (SEED) Company Showcase Program. Based on external reviewer feedback of submitted applications, selected companies will receive financial assistance to cover presentation and registration costs at one industry hosted investor showcase. In the last six years, more than 170 NCI SBIR-funded companies were selected to present at various conferences such as BIO, BioNetwork, MedTech Strategist events, Life Sciences Summit, PMWC, and RESI.

Application Deadline: EOD Tuesday, March 1, 2022

*Incomplete applications will be returned.*

Showcases in which the NCI SBIR program has participated in the past or is considering in the future include but are not limited to:

o    Angel Capital Association Annual Meeting

o    BIO CEO & Investor Conference

o    BIO Annual Meeting

o    BIO Investor Forum

o    BioNetwork

o    Redefining Early Stage Investments (RESI Conference)

o    Life Science Summit

o    MedTech Strategist Innovation Summit

o    The MedTech Conference

o    Precision Medicine World Conference



All small businesses who have received a Phase I NCI SBIR/STTR award in FY2020 or later or received a Phase II NCI SBIR/STTR award in FY2018 or later are eligible to apply. Please note that each company can submit only one application form. If your company has received multiple awards, select the project/product with the greatest commercial potential for an investor event. Companies in all developmental stages are welcome to apply. 


Why should you apply?

  • Our review team includes about 65-80 VCs/strategic partners.  Your application will be reviewed by qualified people in your technology area including some of industry’s top venture capitalists and strategic partners that may be looking for deal flow. Past reviewers have included representatives from AbbVie, ARCH Venture Partners, Johnson & Johnson, Northpond Ventures, OrbiMed, Pfizer, Siemens, and Takeda.
  • We will provide detailed feedback based on investor review and discussion for your application, giving you a chance to learn how investors and strategic partners are viewing your technology.
  • NCI SBIR will use the external review to identify and recommend companies for all of NCI’s Investor Initiatives in 2022 including industry–specific showcases such as BIO or PMWC depending on technology area and product’s developmental stage.
  • You could receive financial assistance for presenting at investor forums.
  • The applications brief SBIR program staff on the key parts of your technology in a way that allows us to share your company’s progress and stage with external investors that we network with at many events.

Note: After you submit your application and during the review process, we may reach out to ask for you to submit a short video pitch that will help us make our final decisions.



NCI SBIR Development Center Points of Contact:

Brittany Connors
Phone: 240.907.6001
Jian Lou


Updated Date: 
April 27, 2022